Mandibular osteosarcoma: diagnosis and treatment

Ferri, Andrea; Bianchi, Bernardo; Ferrari, Silvano

doi:10.1097/moo.0000000000000793

Cited by 7 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The treatment protocol for OSJ is not standardized and varies greatly between institutions [ 50 ]. However, surgical treatment, including radical resection with wide free margins, continues to be the main option with the best prognosis for this type of tumor [ 26 , 28 , 30 , 51 ]. Achieving free margins is considered technically more difficult in the maxilla than in the mandible, with data ranging between 30% and 52% of affected margins after surgery [ 15 , 29 , 52 ].…”

Section: Discussionmentioning

confidence: 99%

Clinical and Pathological Features of Osteosarcomas of the Jaws: A Retrospective Study

Rodriguez-Molinero,

Pozo-Kreilinger,

Ruiz-Roca

et al. 2024

Clinics and Practice

View full text Add to dashboard Cite

Introduction: Osteosarcomas of the jaw (OSJs) are rare tumors with distinct characteristics from osteosarcomas affecting other bones. This study aims to analyze the clinical, pathological, and therapeutic characteristics of OSJs. Methods: A retrospective, descriptive cross-sectional study including patients diagnosed with OSJ registered at the “La Paz” University Hospital, Madrid, was performed. Results: Data of eight patients with a diagnosis of OSJ were obtained during the study period of 22 years (2002–2024). The mean age of the patients was 41 years. The distribution was 1:1 between the maxilla and mandible. Painful inflammation was the most frequent clinical manifestation. Conventional osteoblastic osteosarcoma was the most predominant histological type. Survival rate at 5 years was 50%, which decreased to 25% at 10 years. Conclusions: OSJs differ from conventional osteosarcomas of long tubular bones. Surgery continues to be the mainstay of treatment. However, more studies are needed through which more standardized protocols can be proposed for adjuvant therapeutic management.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical and Pathological Features of Osteosarcomas of the Jaws: A Retrospective Study

Rodriguez-Molinero,

Pozo-Kreilinger,

Ruiz-Roca

et al. 2024

Clinics and Practice

View full text Add to dashboard Cite

show abstract

“…Osteosarcoma is characterized by complex epigenetic features and a high propensity for metastasis, frequently occurring in adolescents ( 44 ). Currently, chemotherapy and surgical interventions are effective predominantly in early-stage osteosarcoma patients ( 45 ).…”

Section: Discussionmentioning

confidence: 99%

Multi-omic validation of the cuproptosis-sphingolipid metabolism network: modulating the immune landscape in osteosarcoma

Li,

Fang,

Liu

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

BackgroundThe current understanding of the mechanisms by which metal ion metabolism promotes the progression and drug resistance of osteosarcoma remains incomplete. This study aims to elucidate the key roles and mechanisms of genes involved in cuproptosis-related sphingolipid metabolism (cuproptosis-SPGs) in regulating the immune landscape, tumor metastasis, and drug resistance in osteosarcoma cells.MethodsThis study employed multi-omics approaches to assess the impact of cuproptosis-SPGs on the prognosis of osteosarcoma patients. Lasso regression analysis was utilized to construct a prognostic model, while multivariate regression analysis was applied to identify key core genes and generate risk coefficients for these genes, thereby calculating a risk score for each osteosarcoma patient. Patients were then stratified into high-risk and low-risk groups based on their risk scores. The ESTIMATE and CIBERSORT algorithms were used to analyze the level of immune cell infiltration within these risk groups to construct the immune landscape. Single-cell analysis was conducted to provide a more precise depiction of the expression patterns of cuproptosis-SPGs among immune cell subtypes. Finally, experiments on osteosarcoma cells were performed to validate the role of the cuproptosis-sphingolipid signaling network in regulating cell migration and apoptosis.ResultsIn this study, seven cuproptosis-SPGs were identified and used to construct a prognostic model for osteosarcoma patients. In addition to predicting survival, the model also demonstrated reliability in forecasting the response to chemotherapy drugs. The results showed that a high cuproptosis-sphingolipid metabolism score was closely associated with reduced CD8 T cell infiltration and indicated poor prognosis in osteosarcoma patients. Cellular functional assays revealed that cuproptosis-SPGs regulated the LC3B/ERK signaling pathway, thereby triggering cell death and impairing migration capabilities in osteosarcoma cells.ConclusionThe impact of cuproptosis-related sphingolipid metabolism on the survival and migration of osteosarcoma cells, as well as on CD8 T cell infiltration, highlights the potential of targeting copper ion metabolism as a promising strategy for osteosarcoma patients.

show abstract

Li–Fraumeni‐associated osteosarcomas: The French experience

Saucier,

Bougeard,

Gomez‐Mascard

et al. 2024

Pediatric Blood & Cancer

View full text Add to dashboard Cite

PurposeDescribe clinical characteristics and outcome of Li–Fraumeni syndrome (LFS)‐associated osteosarcomas.MethodsTP53 germline pathogenic/likely pathogenic variant carriers diagnosed with osteosarcoma in France between 1980 and 2019 were identified via the French Li–Fraumeni database at Rouen University Hospital. Sixty‐five osteosarcomas in 52 patients with available clinical and histological data were included. The main clinical characteristics were compared with data from National Cancer Institute's SEER (Surveillance, Epidemiology, and End Results) for patients of the same age group.ResultsMedian age at first osteosarcoma diagnosis was 13.7 years (range: 5.9–36.7). Compared to unselected osteosarcomas, LFS‐associated osteosarcomas occurred more frequently in patients less than 10 years of age (23% vs. 9%), and when compared with osteosarcomas in patients less than 25 years were characterized by an excess of axial (16% vs. 10%) and jaw sites (15% vs. 3%) and histology with predominant chondroblastic component and periosteal subtypes (17% vs. 1%). Metastases incidence (25%) was as expected in osteosarcomas. After the first osteosarcoma treatment, the rate of good histologic response (62%) and the 5‐year progression‐free survival (55%, 95% confidence interval [CI]: 42.6−71.1) were as expected in unselected series of osteosarcomas, whereas the 5‐year event‐free survival was 36.5% [95% CI: 25.3−52.7] due to the high incidence of second malignancies reaching a 10‐year cumulative risk of 43.4% [95% CI: 28.5−57.5].ConclusionIn osteosarcoma, young age at diagnosis, axial and jaw sites, histology with periosteal or chondroblastic subtype, and synchronous multifocal tumors should prompt suspicion of a germline TP53 mutation. Standard treatments are effective, but multiple malignancies impair prognosis. Early recognition of these patients is crucial for tailored therapy and follow‐up.

show abstract

Mandibular osteosarcoma: diagnosis and treatment

Cited by 7 publications

References 31 publications

Clinical and Pathological Features of Osteosarcomas of the Jaws: A Retrospective Study

Clinical and Pathological Features of Osteosarcomas of the Jaws: A Retrospective Study

Multi-omic validation of the cuproptosis-sphingolipid metabolism network: modulating the immune landscape in osteosarcoma

Li–Fraumeni‐associated osteosarcomas: The French experience

Contact Info

Product

Resources

About